General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises BioXcel Therapeutics on Public Offering of Common Stock

June 25, 2021
Capital markets team represents the clinical-stage biopharmaceutical development company in the offering.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical development company, closed on June 25, 2021 its underwritten public offering of 3,155,000 shares of common stock at a public offering price of US$31.70 per share. In addition, a related party stockholder, BioXcel LLC, granted the underwriters a 30-day option to purchase up to an additional 473,250 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to the Company from the offering were approximately US$100 million, before deducting underwriting discounts and commissions and offering expenses.

Latham & Watkins LLP represents BioXcel Therapeutics in the offering with a capital markets team led by partners Peter Handrinos and Keith Halverstam, with associates Danny Shulman and Paul Rafla.